Maker of Wegovy and Ozempic has 45,000 patients in clinical trials as it seeks to stave off threats from Eli Lilly and Roche
Swiss drugmaker unveils promising data for obesity drug
Long waiting list for drug because of shortage of specialist services could hit patients unable to pay privately
UK pharma body criticises maker of Ozempic and Wegovy over failure to report £7.8mn in transfers of value
Danish maker of Wegovy has little competition in the country and massive demand that it can take advantage of
Move opens market with growing rates of obesity to Danish group’s blockbuster drug
Danish pharma group plans 1.4mn sq ft manufacturing plant in North Carolina to help meet surging demand
Both OZEM and THNR offer very concentrated bets on a fast-moving market
The sector’s holy grail of an effective, easily manufactured weight loss pill does not look imminent
Study opens up potential to tackle a condition with few available treatment options
Trial participants also had cardiovascular benefits regardless of weight
Novo Nordisk, Bill & Melinda Gates Foundation and Wellcome focus on interlinked issues
Danish group beats expectations with first-quarter sales up 24% and raises annual forecast on high demand
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
There is an opportunity for local pharma groups, which Nomura says could take a fifth of the market by 2033
Eli Lilly and Novo Nordisk’s weight-loss drugs have transformed their fortunes but a backlash could be looming
Booming sector raises tough questions for ESG investors
Drugmaker releases promising trial results for a pill and expects to enter China this year
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years
German pharma group finds no unexpected side effects during trial, including at higher doses
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
The coffers of Novo Nordisk’s controlling shareholder have been boosted by diabetes and weight loss drugs
